Peptide Medicine
KPV Peptide: What the Research Shows, Uses, and Safety
Medically reviewed by HealthRX.com Medical Team · Last reviewed
What is KPV?
KPV is a short peptide of three amino acids, lysine, proline and valine. It is the last three residues of alpha-melanocyte-stimulating hormone (alpha-MSH), a natural signaling molecule the body makes. Researchers study KPV because it keeps the anti-inflammatory activity of alpha-MSH without the pigment effects.
Work in the late 1980s identified this C-terminal fragment of alpha-MSH as the part that carries much of the parent hormone's anti-inflammatory activity. [1]
KPV is sold today mostly as a research chemical and, in some places, prepared by compounding pharmacies. It has no recognized therapeutic drug class and no approved use. [3]
How does KPV work?
In laboratory studies KPV lowers inflammation by blocking the NF-kB and MAPK signaling pathways, which reduces output of inflammatory messengers such as TNF-alpha and IL-6. In the gut it is taken up by the PepT1 transporter, which is more active in inflamed tissue.
A 2008 study showed that KPV enters intestinal and immune cells through the PepT1 peptide transporter and reduces inflammation once inside. Because PepT1 is upregulated where tissue is inflamed, uptake is somewhat concentrated at the site of inflammation. [4]
Its anti-inflammatory effect is considered largely independent of the melanocortin receptors that control pigment, which is why it does not tan the skin the way the parent hormone can. Some tissue-specific receptor involvement has been reported, so the picture is not absolute. [5]
What does the research on KPV show?
The strongest evidence is in animal models of colitis, where oral KPV reduced inflammation and tissue damage. It has also shown antimicrobial activity in the laboratory. There are no published human trials, so benefits in people are unproven, and skin or wound-healing claims are extrapolated from related research.
- Inflammatory bowel models: oral KPV reduced colitis severity in mice, with less weight loss and lower inflammatory markers. [4][5]
- Antimicrobial: KPV reduced viability of Staphylococcus aureus and Candida albicans in laboratory tests. [2]
- Skin and wound claims: these are drawn from broader alpha-MSH research, not from human KPV trials. [3]
- Honest framing: all efficacy data is from cells and animals. Human clinical evidence does not yet exist.
How is KPV used and dosed?
There is no established or trial-validated human dose. In research and clinic settings KPV is described orally, topically and by subcutaneous injection, and it is sometimes paired with BPC-157. Any use should be directed by a licensed clinician, and figures seen online are reported ranges, not recommendations.
| Form | Reported use | Notes |
|---|---|---|
| Oral | Discussed for gut-focused use | Favored because of PepT1 uptake in the intestine |
| Topical | Applied to skin | Drawn from alpha-MSH skin research |
| Subcutaneous (compounded) | Provider-directed | No validated human dose; requires prescription and oversight |
Is KPV safe, and what are the side effects?
Human safety is essentially unstudied. Short peptides like KPV were generally well tolerated in animal research, but there is no systematic human safety data. Injectable peptides carry immunogenicity concerns, and gray-market products can have purity or contamination problems.
- No systematic human adverse-event data exists.
- Injectable use carries injection-site and immunogenicity risks.
- Gray-market material may vary in purity, sterility and dose accuracy.
- Effects in pregnancy, breastfeeding, children or with other medications are unknown.
Is KPV legal and FDA approved?
KPV is not FDA approved for any condition. Its compounding status is unsettled: it was removed from the FDA's interim Category 2 list in April 2026, and an FDA advisory committee was scheduled to review it in July 2026 for the Section 503A bulk list. Availability through compounding pharmacies is uncertain.
Because KPV is not an approved medicine, it should only be considered through a licensed provider and a reputable compounding pharmacy, and only if permitted where you live. Products sold as research chemicals are not intended for human use and are not quality assured. [3][6]
How does KPV compare with other peptides?
| KPV | BPC-157 | TB-500 | |
|---|---|---|---|
| Primary focus | Calming inflammation | Tissue and tendon repair | Tissue repair and mobility |
| Origin | Fragment of alpha-MSH | Synthetic sequence | Fragment of thymosin beta-4 |
| Best evidence | Animal colitis models | Preclinical | Preclinical |
| FDA approved | No | No | No |
Frequently asked questions
Is KPV FDA approved or proven to work in people?
No. KPV is not FDA approved for any condition, and there are no published human trials showing it works. The evidence is limited to laboratory and animal studies, mostly in models of colitis.
What does the research on KPV actually show?
In mice, oral KPV reduced chemically induced colitis, and in cell studies it lowers inflammatory signaling. It also showed some antimicrobial activity. Animal and cell results do not reliably predict safety or benefit in humans.
Is KPV safe?
Its human safety is essentially unstudied. Short peptides were generally well tolerated in animal research, but there is no human safety data, and gray-market products can have purity or dosing problems. Use in pregnancy or with other medicines is unknown.
Can I get KPV from a pharmacy?
It depends and is in flux. KPV was removed from the FDA's restrictive Category 2 list in April 2026 but has not been approved or added to the Section 503A compounding list. An FDA committee was set to review it in July 2026.
How is KPV different from BPC-157?
Both are unapproved peptides studied only in animals and cells. KPV comes from the hormone alpha-MSH and is studied as an anti-inflammatory. BPC-157 is a synthetic peptide studied more for tissue repair. Neither has human trial proof.
Citations
- Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. 1989;3(11):2282-2284.
- Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000;67(2):233-239.
- Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alpha-MSH and related tripeptides: biochemistry, antiinflammatory and protective effects. Endocr Rev. 2008;29(5):581-602.
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331.
- U.S. FDA. Pharmacy Compounding Advisory Committee, meeting notice (Section 503A bulk drug substances), Federal Register, April 16, 2026.
This guide is educational and is not a substitute for individualized medical advice. KPV is prescription-only and requires evaluation by a licensed provider.